Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Novo Nordisk has been on the hunt for differentiated ... a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule that blocks ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

(Reuters) -Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen ...